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Abstract 
Purpose 
Iron deficiency anaemia (IDA) is a global public health problem. Treatment with the 
standard of care ferrous iron salts may be poorly tolerated leading to noncompliance 
and ineffective correction of IDA. Employing supplements with higher bioavailability 
might permit lower doses of iron to be used with fewer side effects, thus improving 
treatment efficacy. Here we compared the iron bioavailability of ferrous sulphate 
tablets with alternative commercial iron products, including three liquid based 
supplements. 
Methods 
Iron bioavailability was measured using Caco-2 cells with ferritin formation as a 
surrogate marker for iron uptake. Statistical analysis was performed using one-way 
ANOVA followed by either Dunnett’s or Tukey’s multiple comparisons tests. 
Results 
Spatone Apple® (a naturally iron-rich mineral water with added ascorbate) and Iron 
Vital F® (a synthetic liquid iron supplement) had the highest iron bioavailability. 
There was no statistical difference between iron uptake from ferrous sulphate tablets, 
Spatone® (naturally iron-rich mineral water alone) and Pregnacare Original® (a multi-
mineral/vitamin tablet).  
Conclusion 
In our in vitro model naturally iron-rich mineral waters and synthetic liquid iron 
formulations have equivalent or better bioavailability compared with ferrous iron 
sulphate tablets. If these results are confirmed in vivo, this would mean that at risk 
groups for IDA could be offered a greater choice of more bioavailable and potentially 
better tolerated iron preparations. 
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Introduction 
 
Iron deficiency is a global health problem; 2 billion people suffer from anaemia and 
the World Health Organization (WHO) estimates that iron deficiency accounts for 
50% of these cases [1]. Although the prevalence of iron deficiency anaemia (IDA) is 
highest in developing countries, inadequate iron status is also a significant public 
health problem in developed countries in high-risk groups including the elderly, post-
bariatric surgery patients, toddlers, and pregnant women and women of child bearing 
age [2,3].   
 
Three ferrous iron salts, sulphate, fumarate and gluconate, are the standard 
recommended supplements for IDA [4,5]. Clinical trials with pregnant women 
document that these iron supplements do improve IDA [6], however, non-compliance 
secondary to supplement-associated gastro-intestinal (GI) problems, such as 
constipation, black stools, nausea, reflux and vomiting, means that real life efficacy 
may be low [7-9]. Pregnancy itself induces gastrointestinal symptoms, related to the 
mechanical effects of the growing foetus, changes in water homestasis, and hormonal 
effects on GI motility -  all of which contribute to increased incidence of reflux, 
constipation and bloating [10,11].  Higher doses of iron increase gastro-intestinal (GI) 
symptoms in pregnant women [12], and studies document that lower doses are 
associated with fewer GI symptoms [6,13], thus it is possible that the use of iron 
preparations with higher bioavailability, enabling lower absolute doses of iron to be 
ingested, may cause less GI upset.  
 
IDA is associated with increased health risks to both mother and foetus (reviewed in  
[14]), and it is therefore vital that effective supplement forms are available to 
pregnant women. A human volunteer study demonstrated that iron absorption from a 
naturally iron-rich mineral water (Spatone Iron-Plus) was higher compared with 
ferrous sulphate tablets (FeSO4) [15]. Furthermore, a subsequent study looking 
specifically at pregnant women with IDA found that the mean absorption from 25 mg 
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of Spatone derived Fe was 28% - comparable or greater to that reported from a higher 
dose of FeSO4 [16].  
 
The physical form of iron administered in supplements could have a bearing on 
bioavailability. A recent in vitro study found that dissolution rates varied significantly 
amongst different iron tablet formulations; FeSO4 conventional-release tablets 
dissolved most quickly at 48-64 minutes, and this was associated with the highest iron 
uptake in the in vitro Caco-2 cell model used in this study [17].  We hypothesized 
therefore that liquid iron formulations, whether naturally occurring or synthetic, might 
provide alternative supplement forms that have higher bioavailability compared with 
iron delivered in tablet form.  
 
In this study we have employed the Caco-2 cell in vitro digestion model to assess iron 
bioavailability, using cell ferritin as a surrogate marker for iron absorption, from five 
commercially available iron formulations including three liquid iron supplements 
[18]. This model is used worldwide to measure iron bioavailability from different 
substances, and has been validated by human studies [19]. We compared two 
naturally mineral rich waters, Spatone® and Spatone Apple® (Spatone with added 
apple flavour and ascorbate), Iron Vital F® (a synthetic liquid iron supplement with 
added ascorbate and other micronutrients), immediate release FeSO4 tablets, and 
Vitabiotics Pregnacare® (a multivitamin and mineral tablet marketed to pregnant 
women). 
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Materials &Methods 
 
Reagents 
Chemicals, hormones and enzymes were purchased from Sigma-Aldrich, UK, unless 
otherwise noted.  Cell culture media, flasks, tissue culture plates and culture reagents 
were obtained from Thermo Fisher Scientific, and acids used in ICP analysis, 
digestions and for glassware cleaning were purchased from VWR, UK. Glass and 
plastic ware used in experiments were soaked in 10% trace metal grade 68% nitric 
acid for 24 hours prior to use, and then rinsed with 18 mΩ pure water. 
 
Commercial iron preparations were purchased from Boots Pharmacy, UK. These 
consisted of: Spatone® & Spatone Apple® (A Nelson & Co Ltd, UK); Iron Vital F® 
(Anton Hubner Gmbh & Co Germany); Pregnacare Original® (Vitabiotics Ltd. UK), 
and Almus Ferrous Sulphate tablets (Almus Pharmaceuticals, UK). Table one 
provides iron concentration for the different formulations.  
 
Cell culture 
Caco-2 cells (TC7 clone), gifted to the Sharp lab by Monique Rousset and Edith Brot-
Laroche [20], were used from cell passages 46-49. The TC7 clone has been validated 
for use in studies on iron metabolism [21], and has been used in our previous 
published work on iron bioavailability [22]. Cells were grown in T75 tissue culture 
flasks and subcultured every 7 days. For experiments, cells were grown in 6 well 
tissue cultures plates seeded at a density of 1x10 4 cells/cm2 and used on days 13-15 
post seeding in the method developed by the Glahn lab [18,19].  Cells were grown in 
Dulbecco’s Modified Eagle Medium (DMEM, Gibco, 41965) supplemented with 10% 
v/v fetal bovine serum (LCG Standards, 30-2020), 1% penicillin-streptomycin, 4 
mmol/L L-glutamine, 1% non-essential amino acids, and Plasmocin 5 mg/ml (Source 
Bioscience). 
 
24 hours prior to the initiation of in vitro digestion experiments media was changed to 
supplemented MEM without foetal bovine serum but with 10 mmol/L PIPES 
(piperazine-N, N’-bis- [2-ethanesulfonic acid]), 1% antibiotic/ antimycotic solution, 
11 mmol/L hydrocortisone, 0.87 mmol/L insulin, 0.02 mmol/L sodium selenite 
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(Na2SeO3), 0.05 mmol/L triiodothyronine and 20 mg/L epidermal growth factor, as 
developed by Glahn et al, in order to ensure adequate cell growth but with low basal 
media iron levels [18,19].  
 
Iron supplements and in vitro digestions 
Iron-containing tablets were sealed inside a disposable plastic sleeve and crushed with 
a mortar and pestle; the particles were then solubilised in 250 ml 0.2 mol/L 
hydrochloric acid (HCl) [23]. Liquid formulations were used directly from the sachets 
(Spatone®and Spatone Apple®), or the bottle (Iron Vital F®). The supplements all had 
different iron concentrations; therefore, the volumes of prepared solutions, or liquid 
supplements, were adjusted (based on the manufacturers reported iron concentrations) 
to achieve a final digest iron concentration of 50 µmol/L. 
 
Fresh tablet solutions were prepared and new sachets were used for every experiment. 
In addition, all experiments had a set of controls consisting of: a digest with no added 
iron to ensure no iron contamination of our system; a reference digest of 50 µmol/L 
Fe added as Fe solubilized in 1% HCl (High-Purity Standards, 100026-2); and a 
positive control digest of 50 µmol/L Fe and 500 µmol/L ascorbate.  
 
Iron levels of digests were quantitatively analysed by Inductively Coupled Plasma – 
Optical Emission Spectrometry (ICP-OES). All iron containing digests, and undiluted 
samples of Spatone® and Spatone Apple®, were subjected to microwave digestion 
using an accelerated reaction system (CEM MARS 5H with XP-1500 vessels). 0.5 ml 
of the solutions (in triplicate) was added to 5.0 ml concentrated 68% trace analysis 
grade nitric acid. Samples were processed for 20 minutes at 400-psi pressure and 
1200-W power. After digestion samples were reconstituted with 50 ml 18 mΩ water 
and aliquots used to measure iron levels on a Perkin Elmer Optima 4300 DV ICP-
OES. 
 
Digests were prepared as previously described [22].  Briefly, iron solutions were 
added to 10 ml of 140 mmol/L NaCl and 5 mmol/L KCl followed by the sequential 
addition of pepsin (1 hour in the shaking incubator, pH 2 digests), and then bile and 
pancreatin digestive enzymes (1 hour in the shaking incubator, pH 7 digests) to mimic 
the digestive process. 1.5 ml of the above digests was then placed in a chamber 
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suspended over a layer of Caco-2 cells grown on the bottom of the tissue culture wells 
of a six well plate. The upper chamber was created using a 15,000 molecular weight 
cut-off dialysis membrane (Tubing Spectra/Por 7 dialysis membrane, Fisher 
Scientific) fitted over a Transwell insert and held in place with a silicon ring (Web 
Seal). Plates were placed on a platform fitted Multi-function 3D rotator (Fisher 
Scientific PSM3D) set at 6 oscillations per minute in a 37°C incubator with a 5% 
CO2/95% air atmosphere at constant humidity for 60 minutes. Inserts were then 
removed and an additional 1 ml of supplemented MEM added to the cells, which were 
returned to the incubator for a further 22 hours, and then harvested for ferritin. All 
supplements were tested on three separate occasions, with n=6 for each treatment. 
 
Direct application of iron supplements onto Caco-2 cells to assess dose and treatment 
duration responses 
Caco-2 cells were seeded and maintained as described for in vitro digestion 
experiments.  On the day of the experiment fresh solutions of Spatone®, Spatone 
Apple® and ferric ammonium citrate (FAC) were mixed with plain MEM (herein 
referred to as MEM) and placed directly onto the cell monolayers at iron 
concentrations of 10, 30 and 100 µmol/L. In order to assess ferritin formation as a 
function of treatment duration/time, one set of cells was treated for a full 24 hours, 
while another set was treated for fours hours (begun 20 hours after media was 
changed to MEM). At the end of both time periods cells were harvested for ferritin. 
Experiments were repeated on three separate occasions with n = 6 for each treatment. 
  
Cell harvest and ferritin analysis 
Cells were harvested as previously described [22].  Briefly, rinsed cell monolayers 
were detached with the proprietary cell lysis buffer CelLytic™ (Sigma-Aldrich) with 
added protease inhibitor. Cells were shaken for 15 minutes on ice on an orbital shaker 
at 300 rpm, and then spun at 6000 x g for 6 minutes in a 5804R Eppendorf centrifuge. 
The supernatant was aspirated and stored in a -80°C freezer. For analysis, samples 
were thawed on ice and ferritin measured with SpectroFerritin MT Enzyme Linked 
Immunoassay (ELISA; RAMCO). Final ferritin levels were adjusted for cell protein 
also measured from the supernatants using Pierce Protein BCA Assay (Fisher 
Scientific, 23227). 
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Statistical analysis 
Statistical analysis of the data was performed using GraphPad Prism (v.6.0c 
GraphPad Software, San Diego, CA). Digest experiments were analysed using the 
statistical methods of Motulsky [24].  Data are presented as means ± S.E.M and were 
analysed by one-way ANOVA followed by Tukey’s multiple comparisons test (all-
pairwise across experimental groups); where the comparison was made to a single 
control Dunnett’s post-hoc test was used. Except as noted differences between means 
were considered significant at p ≤ 0.05. 
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Results 
 
Iron supplements contained different iron concentration (Table 1). Each was prepared 
to give a notional iron concentration of 50 µmol/L. However, ICP-OES measurements 
revealed that the iron content of digests varied between different iron sources (Table 
2). To adjust Caco-2 cell ferritin levels for the variable iron content of digests we 
carried out a dose-response study to measure ferritin formation following exposure to 
different concentrations of iron (Supplementary figure 1). The dose response study 
demonstrated that ferritin levels in digests were proportional to the log of iron 
concentration, and thus measured ferritin levels were adjusted using the equation: Fadj 
= F x ln(50)/ln(Feicp) where Fadj equals adjusted ferritin, and Feicp equals ICP 
measured digest iron levels. 
 
Caco-2 cell ferritin levels were highest in cells exposed to Spatone Apple® (Figure 1). 
Levels were approximately 500% higher than both Spatone® original and FeSO4  
tablets. Iron Vital F® (IVF) induced ferritin formation was approximately 100% 
higher compared with FeSO4, Spatone®, and Pregnacare Original® (PG) but was only 
about a third that of Spatone Apple® (Figure 1). Ferritin formation following exposure 
to Pregnacare Original® was equivalent to that of cells treated with Spatone® and 
FeSO4. 
 
We further investigated the effects of Spatone® and Spatone Apple® on ferritin levels 
in Caco-2 cells over a range of iron concentrations, and following different exposure 
times. Exposure to Spatone Apple® for either 4 h (Figure 2A) or 24 h (Figure 2B) 
resulted in significantly enhanced ferritin levels at all concentrations compared with 
the untreated controls. Spatone Apple®-induced ferritin levels were significantly 
higher than those produced following exposure to iron alone (all concentrations at 
both 4 h and 24 h time points) and Spatone® original (all concentrations at 24 h; 30 & 
100 µmol/L at 4 h).  
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Discussion 
 
Current strategies for the treatment of IDA are based on oral ferrous iron 
supplements; however, these are poorly tolerated by patients due to a range of GI 
side-effects [6-9]. This in turn leads to poor compliance with therapy, which has 
consequences for the efficacy of treatment.  Iron preparations with higher 
bioavailability, thus enabling lower absolute doses of iron to be ingested, may cause 
less GI upset and be better tolerated by patients. This notion is supported by a study 
undertaken in pregnant women who had been non-compliant with taking FeSO4 
tablets, and were switched to Spatone iron rich water; 57% of subjects were compliant 
with the new iron supplement compared with 67% in the controls given placebo (plain 
water), and dyspepsia scores did not differ between the two groups [25].  
 
We have compared the bioavailability of a range of commercially available iron 
supplements using a well-characterized in vitro digestion model [18,19]. Spatone, and 
ferrous sulphate tablets had equivalent  bioavailability in the in vitro model, which is 
consistent with previous absorption studies in human volunteers [16]. The iron in 
Spatone® is FeSO4; this suggests that being in liquid form per se doesn’t increase iron 
bioavailability. Spatone Apple® demonstrated the highest iron bioavailability in the in 
vitro model, followed by the synthetic liquid iron formulation Iron Vital F®; this 
result remained highly significant even after adjustment for the increased iron in 
Spatone Apple® digests. Both Spatone Apple® and Iron Vital F® contain added 
ascorbate, a known enhancer of iron uptake. While Spatone Apple® has 80 mg 
ascorbate/sachet  (E Hunt, Product & Consumer Information Officer for Nelson & 
Co., personal communication, 2014) giving an iron:ascorbate molar ratio of 1:16, the 
iron:ascorbate ratio in Iron Vital F is 1:6 according to the supplement label.  The 
enhancing effects of ascorbate on iron bioavailability are dose dependent [26], 
therefore the higher ascorbate:iron ratio in Spatone Apple® may explain the difference 
in iron uptake between the two supplements.  Furthermore, Iron Vital F®, according to 
the manufacturer’s ingredients list, also contains plant extracts, pectin and thickening 
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agents. These dietary factors are sources of polyphenols and phytates, both of which 
inhibit iron absorption and are only partly counteracted by ascorbate [26].  
Interestingly, Vitabiotics Pregnacare® had the same bioavailability as FeSO4, despite 
having added ascorbate (70 mg/tablet). The iron:ascorbate molar ratio, however, is 
only 1:4, which may not be optimal for improving iron uptake. In addition, the 
presence of other minerals contained in Pregnacare®, such as zinc, may partially 
inhibit iron uptake [27]. 
 
Pregnant women are at high risk for IDA [28], however iron supplement 
recommendations during pregnancy differ between countries. The WHO and the 
United States of America (USA) recommend that all pregnant women receive 
prophylactic prenatal iron [29-31].  Currently, the United Kingdom (UK) does not 
suggest routine prenatal iron supplementation [32]; historically pregnant women in 
the UK were advised to take iron but this was found to be either ineffective [33], or to 
have no demonstrated benefit on maternal or foetal outcomes [34,35]. Recent research 
may challenge current UK guidelines [36]; two large systematic reviews with meta-
analyses found that daily prenatal iron reduced maternal anaemia, IDA and risk of 
foetal low birth weight [37,38]. However, one of the reviews noted that dose and 
regimen recommendations for routine iron supplementation need refining and 
updating [37], and within this context our results suggest that further research with the 
tested formulations used in our study are warranted.  
 
Another group that might benefit from both Spatone Apple® and Iron Vital F® are 
post-bariatric surgery patients who are at high risk of IDA [39-41], and in whom 
treatment with standard iron tablets is often ineffective [42,43]. In one study post-
operative gastric bypass patients given 100 mg FeSO4 tablets as an oral challenge 
absorbed inadequate amounts of iron as measured by change in serum iron 
concentration [44]; altered gut physiology after bariatric surgery may not allow for 
iron absorption from FeSO4 tablets. Furthermore, several studies have also 
documented low vitamin C levels in patients after bypass procedures [45,46], 
therefore liquid iron preparations with added ascorbate - such as Spatone Apple® and 
Iron Vital F® (which also has other micronutrients) - may be helpful in this 
population.  
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The data presented here for Spatone Apple® suggest that this, or similar products, are 
highly bioavailable as they gave rise to a rapid increase in cell ferritin in our in vitro 
model. Furthermore, 10 µmol/L iron given as Spatone Apple® gave a comparable 
ferritin response to 100 µmol/L ferric ammonium citrate and a higher ferritin level 
than 100 µmol/L FeSO4 (from Spatone®). An important caveat is that we have only 
performed in vitro studies to date. The bioavailability of Spatone Apple® has not been 
assessed in human volunteers, and our data suggest that these studies are warranted. 
The Caco-2 in vitro digestion model provides a validated method for screening iron 
bioavailability of a range of compounds and test meals. Furthermore, it has been 
shown to predict the direction, but not necessarily the magnitude, of iron 
bioavailability in humans [47]. If our in vitro results are confirmed in vivo it would 
suggest that lower doses of a more bioavailable iron form could be effective in 
combating iron deficiency.  This would be particularly advantageous for groups who 
are both at increased risk of IDA and less tolerant to high doses of iron, such as 
pregnant women. 
 
In conclusion, the results of this in vitro study demonstrate that naturally iron-rich 
mineral waters, or synthetic liquid iron formulations, are equivalent to the standard of 
care FeSO4 recommended for IDA; and those with added ascorbate have increased 
bioavailability.  If these results are confirmed in randomized control studies in human 
volunteers at risk for IDA, such subjects could then be offered a greater choice of 
more bioavailable and potentially better tolerated iron preparations. 
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Table 1 Manufacturers’ information including reported iron content for tested iron preparations 
Product name Reported iron content Manufacturer 
Spatone® 0.25 mg FeSO4/ml  
A Nelson & Co Ltd  
(UK) 
Spatone Apple®  0.20 mg FeSO4/ ml 
A Nelson & Co Ltd  
(UK) 
Iron Vital F®  1 mg iron-II-gluconate/ml Anton Hubner Gmbh & Co (Germany) 
Pregnacare Original® 51.4 mg ferrous fumarate equivalent to 17 mg ferrous iron/tablet 
Vitabiotics Ltd.  
(UK) 
Almus Ferrous 
Sulphate tablets  
200 mg FeSO4 equivalent to 65 mg ferrous 
iron/tablet 
Almus Pharmaceuticals  
(UK) 
 
 
 
Table 2 Iron digest levels and Caco-2 cell ferritin after treatment with iron supplements - unadjusted 
for iron digest levels  
Product name Digest iron concentrations  (mg/L) ng ferritin/mg protein (unadjusted) 
FeSO4 2.80±0.10(0%) 11.82±0.67 (0%) 
Iron Vital F®(IVF) 2.90±0.37 (4%) 25.76±2.07 a (118%) 
Pregnacare Original®(PG) 2.83±0.68 (1%) 10.35±0.82 (-12%) 
Spatone® 3.40±0.62 (18%) 12.24±0.91 (4%) 
Spatone Apple® 4.00±0.75*(30%) 83.94±4.46 b (610%) 
Ferritin levels of Caco-2 cells unadjusted for differing digest iron levels as measured by ICP-OES.  Expressed as the mean ± SEM.  
Means with different superscript letters or asterisk in a column are statistically different. Percentage figures in parenthesis by 
digest iron levels is the percent by which the mean digest iron levels of other formulations compared with mean FeSO4 iron digest 
levels; percentage figures in parenthesis by ferritin values are the percent by which the mean ferritin levels of cells treated with the 
other formulations compared with ferritin of FeSO4 treated cells. Digest iron concentrations for IVF, PG and Spatone®, were not 
statistically different from that of FeSO4, however digest iron concentrations in Spatone Apple® were significantly different based 
on one-way ANOVA followed by Tukey’s multiple comparison test (p<0.05). Ferritin levels were highest in Spatone Apple® 
treated cells followed by IVF; levels of the three other treatments were not statistically significantly different based on one-way 
ANOVA followed by Tukey’s multiple comparison test (p<0.05) 
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Fig. 1:  Comparison of ferritin formation from digests with different commercial iron 
formulations adjusted for measured iron levels in digests 
Measurement of Caco-2 cell ferritin formation from digests of FeSO4 tablets, Iron Vital F® (IVF, a 
synthetic liquid iron supplement), Vitabiotics Pregnacare® tablets (PG, a mineral and multivitamin 
supplement marketed to pregnant women), Spatone® and  Spatone Apple® (naturally iron-rich mineral 
waters, the latter with added ascorbate). Digests with no added Fe (Blank) were used to rule out iron 
contamination; digests with Fe alone and Fe plus ascorbic acid (Fe + AA) were used as reference 
controls and positive controls, respectively (not unadjusted for digest iron levels). Treatment with 
Spatone Apple® yielded the highest ferritin levels followed by IVF treatment; ferritin levels from the 
three other supplements were equivalent. Values are means of data adjusted for the iron content of the 
digests (as determined by microwave analysis) ± SEM, n=18. Based on an ANOVA (p<0.0001) with 
Tukey’s multiple comparisons test post-hoc analysis done on an all-pairwise basis after log adjustment, 
bar values with no letters in common are significantly different (p ≤ 0.01) 
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Fig. 2a:  Caco-2 cell ferritin levels as a function of iron dose and time – 4 h exposure  
Caco-2 cells were treated for four hours with three different concentrations of iron. Ferritin levels 
increased as a function of concentration with treatments with Spatone® and Spatone Apple®; this only 
reached statistical significance for Spatone Apple®. Ferritin levels were highest after treatment with 
Spatone Apple® at all three iron doses tested. Asterisks represent treatments with mean values of 
ferritin that are significantly greater than the blank control value (labelled untreated) based on 
Dunnett’s multiple comparisons test.  Columns connected by lines have significantly different means 
from one another based on ANOVA followed by Tukey’s multiple comparisons test where the Tukey’s 
adjusted p-value is shown within the line (p ≤ 0.05 is considered significant) 
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Fig. 2b:  Caco-2 cell ferritin levels as a function of iron dose and time – 24 h exposure  
Caco-2 cells were treated for twenty-four hours with three different concentrations of iron. Ferritin 
levels increased as a function of concentration with treatments with Spatone® and Spatone Apple®; this 
only reached statistical significance for Spatone Apple®. Ferritin levels were highest after treatment 
with Spatone Apple® at 30 and 100 µmol/L iron. Asterisks represent treatments for which mean values 
of ferritin are significantly greater than the blank control value (labelled untreated) based on Dunnett’s 
multiple comparisons test. Columns connected by lines have significantly different means from one 
another based on ANOVA followed by Tukey’s multiple comparisons test where the Tukey’s adjusted 
p-value is shown within the line (p ≤ 0.05 is considered significant) 
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Supplementary fig.1: Caco-2 cell ferritin levels as a function of iron dose  
Caco-2 cells were treated for 24 hours with increasing concentrations of iron ranging from 1-100 
µmol/L. Ferritin levels increased as a function of the log of iron concentration   
 
 
 
 
 
 
 
 
 
